A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

NCT04644484 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Rabies
Communicable Disease
Virus Diseases
Rhabdoviridae Infections
Mononegavirales Infections
RNA Virus Infections

Interventions

BIOLOGICAL: SYN023
BIOLOGICAL: Human Rabies Immune Globulin (HRIG)
BIOLOGICAL: Rabies Vaccine

Sponsor

Synermore Biologics (Suzhou) Co., Ltd.

Collaborators

[object Object]